NASDAQ$TBPH
Theravance Biopharma Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021.
Theravance Biopharma reported their Q4 and full year 2021 financial results. YUPELRI saw the highest quarter of net sales since its launch. GSK’s TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication. The company expects to become sustainably cash-flow positive beginning the second half of this year.
- YUPELRI saw the highest quarter of net sales since its launch.
- GSK’s TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication.
- Strong performance by YUPELRI in Q4 and into 2022 will enable investment in the inhaled JAK inhibitor respiratory pipeline.
- The company remains on target to become sustainably cash-flow positive beginning the second half of this year.
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$14.9M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Forward guidance
Theravance Biopharma will hold a conference call and live webcast accompanied by slides today at 5:00 pm ET / 2:00 pm PT / 10:00 pm GMT.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+0.5%
Avg return
30 days after
53%
26 / 49 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.9% | +2.0% | — | |
| Q1 2026 | +0.4% | -2.8% | -3.8% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q2 2025 | +4.2% | +14.2% | +20.0% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro